Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

NCT03190265 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: GVAX Pancreas Vaccine
DRUG: CRS-207
DRUG: CRS-207

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]